durvalumab
| Brand name | Imfinzi |
|---|---|
| Active ingredient | durvalumab |
| Strength | 120MG/2.4ML (50MG/ML) |
| Dosage form | Injection |
| Route | Intravenous |
| Modality | Biologic |
| FDA approval | May 2017 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.